El anticuerpo #aducanumab reduce las placas A- Beta de la enfermedad de #Alzehimer Bastante prometedor The antibody #aducanumab reduces Aβ plaques in #Alzheimer’s disease #Neurociencias #Neurosciencie | Nature https://t.co/Y3zbCETnuE
RT @bintburton: The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. With increasing number of cases of Alzheimer's a timely…
Wait, what..? In shocking reversal, Biogen to submit experimental Alzheimer’s drug for approval https://t.co/4cndRZPfwL via @statnews Read the original paper by Sevigny et al. Nature, here https://t.co/9OQ77LAuOO News and Views by Eric Reiman, here http
@RebeccaWellsMD @rburstein16 @daviddodick @SHSHeadache @AANMember Um sorry - antibody targeting of brain disorders - for at least two decades https://t.co/BI83PlKHdp and still going strong https://t.co/RvYtgNRGdJ
https://t.co/bsIRKh4FD9 So sad how we live inn a society where we have to drop dead!
Forbes MiaFarrow This is the one that's important! I have followed this drug & know what the experts say. Dale Denney Dr. Sanjay Gupta Sad when society wants people to "Drop Dead". https://t.co/bsIRKh4FD9
@tarahaelle @jamesheathers @chrishendel @AHCJ_Pia @justsaysinmice Now. When someone is trying to calculate translational success rate, this one goes in the red column for team mice. It slowed disease progression and cleared plaques in mice. Super promising
アミロイドβに対する抗体開発↓ https://t.co/SRs331Tb3A でもどれだけ抗体がBBBを通過できるのだろう？ 現在は抗体を脳に届ける研究も進んでいる↓ 『Discovery of novel blood brain barrier targets to enhance brain uptake of therapeutic antibodies（Neuron）』
RT @CambridgeNeuro1: Tragically, less than three years after this exciting Nature paper showing aducanumab reduces Aβ plaques in an Alzheim…
Tragically, less than three years after this exciting Nature paper showing aducanumab reduces Aβ plaques in an Alzheimer’s disease model and in people... the two phase 3 trials are stopped early on the grounds of futility. https://t.co/5icTEwIeLZ
RT @AntHolmes27: Biogen halts Alzheimer's drug trials in major setback for biotech. Another expensive PhIII failure despite promising precl…
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease https://t.co/NdFBDEH15j
Biogen halts Alzheimer's drug trials in major setback for biotech. Another expensive PhIII failure despite promising preclinical data (https://t.co/DBUbDryTD9). Treating AD is complex & we need new preclinical models based on human biology. https://t.c
Could this be the return of successful antibody treatment for Alzheimer's? Sevigny et al. at Biogen have shown that aducanumab has the potential to reduce characteristic Aβ plaques commonly associated with Alzheimer's pathology. https://t.co/Z0OJxnpkgb htt
@amitvkhera @psychgenomics Aducanumab (antibody against AB) first AD drug to show (highly significant) effect on plaques on PET and had nominal effect on MMSE in phase 2 of prodromal to mild AD (https://t.co/L7OFn0yBEn): results from phase 3 in 2019
The academic journal article that the about article was based on...https://t.co/erNJqgINrp. My cousin Robert Scannevin, is one of the authors!